Latest news with #BharatSerumsandVaccines
&w=3840&q=100)
Business Standard
22-05-2025
- Business
- Business Standard
Mankind Pharma shares slide 3% as Q4 profit declines; details here
Shares of Mankind Pharma dropped over 3 per cent on Thursday as the company reported a 10 per cent fall in consolidated net profit for the March quarter of 2024-25 (Q4 FY25). The Delhi-based pharma major's stock fell as much as 3.22 per cent during the day to ₹2,450 per share, the biggest intraday fall since May 2 this year. The stock pared losses to trade 2.1 per cent lower at ₹2,478 apiece, compared to a 1 per cent decline in Nifty 50 as of 9:32 AM. Shares of the company extended losses to their fourth day and have fallen over 6 per cent from their recent highs of ₹2,610, which it hit earlier this month. The counter has fallen 14 per cent this year, compared to a 3.7 per cent advance in the benchmark Nifty 50. Mankind Pharma has a total market capitalisation of ₹1.01 trillion, according to BSE data. Mankind Pharma Q4FY25 results Mankind Pharma posted a 10 per cent fall in consolidated net profit Q4 FY25 at ₹424.65 crore from ₹476.59 crore in the same period last financial year. The pharma company's revenue from operations rose to ₹3,079 crore in Q4, a 27 per cent year-on-year (Y-o-Y) surge from ₹2,422 crore. At the operating level, Mankind's earnings before interest, tax, depreciation, and amortisation (Ebitda) rose to ₹686 crore, with an Ebitda margin of 22.3 per cent in the March quarter. This compares to ₹589 crore and 24.3 per cent, respectively, in the same period last financial year. The company reported that its domestic business revenues witnessed Y-o-Y growth of 18 per cent to ₹2,544 crore in the fourth quarter from ₹2,155 crore in Q4 FY24. It added that this growth was partially supported by continued outperformance in the chronic segment, at 1.3 times the Indian pharma market. Mankind Pharma management commentary Rajeev Juneja, vice-chairman (VC) and managing director (MD), said the company has achieved a healthy revenue growth in Q4. This was driven by strong growth in chronic therapies, recovery in the consumer segment and consolidation of Bharat Serums and Vaccines (BSV), he added. 'Recent key launches like Empagliflozin, Inclisiran and Vonoprazan were among the top five in their respective categories,' the company said in its investor presentation. About Mankind Pharma The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across as well as several consumer healthcare products. It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS vitamins /minerals/nutrients and respiratory.
Business Upturn
22-05-2025
- Business
- Business Upturn
Mankind Pharma shares drop over 2% as Q4 profit declines 10% and margins miss estimates
By Aditya Bhagchandani Published on May 22, 2025, 09:23 IST Shares of Mankind Pharma slipped 2.15% to ₹2,477.00 in early trade on Wednesday after the company reported weaker-than-expected quarterly earnings. The stock had closed at ₹2,531.40 in the previous session. The Delhi-based pharmaceutical firm posted a 10% year-on-year decline in consolidated net profit for Q4 FY25 at ₹424.65 crore, down from ₹476.59 crore in the same quarter last year. While revenue from operations surged 27% YoY to ₹3,079 crore from ₹2,422 crore, the market was disappointed by margin performance. EBITDA for the quarter stood at ₹686 crore compared to ₹589 crore last year. However, EBITDA margin contracted to 22.3% from 24.3%, falling short of analyst expectations. The company also issued margin guidance for FY26 that was below Street estimates. Vice-Chairman and Managing Director Rajeev Juneja attributed revenue growth to strong traction in chronic therapies, recovery in the consumer segment, and the consolidation of Bharat Serums and Vaccines (BSV). Mankind's domestic market share rose from 4.4% in March 2024 to 4.8% in March 2025, driven by growth in the gynaecology segment. Despite revenue momentum, concerns over profitability and guidance led to negative investor sentiment on Wednesday. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
